Screener
Syndax Pharmaceuticals SNDX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (34,202) | (83,757) |
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
| Net loss | $(42,673) | $(84,846) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's interest expense?
- Syndax Pharmaceuticals (SNDX) reported interest expense of $0 in Q1 2026.
- How has Syndax Pharmaceuticals's interest expense changed year-over-year?
- Syndax Pharmaceuticals's interest expense decreased by 100.0% year-over-year, from $2K to $0.
- What is the long-term trend for Syndax Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's interest expense has grown at a -76.3% compound annual growth rate (CAGR), from $1.91M to $6K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Syndax Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude